I am issuing a Buy recommendation on AMAG Pharmaceuticals (NSDQ: AMAG), a biotech company focusing on improving treatments for common but serious diseases such as complications of pregnancy and anemia. The stock is starting to show signs of accumulation and could deliver a significant intermediate term gain. Buy AMAG Pharmaceuticals up… Read More
Alerts
Shares of Airgain (NSDQ: AIRG) hit their $16 sell stop last week and we are closing out this position. We held the stock for two months and took profits on one half of the position after the shares exploded up in response to a better than expected earnings report in November. Read More
I am recommending the purchase of Bristol-Myers Squibb Company (NYSE: BMY) up to $63, a leading global pharmaceutical company with a large oncology presence. The stock is starting to outperform the rest of the big pharma sector which suggests that there is a possible positive surprise in the offing, perhaps… Read More
During an “Investor Day” presentation to Wall Street analysts this morning in Manhattan, Argos Therapeutics (ARGS) confirmed that the critical ADAPT-3 trial for its AGS-003 cancer immunotherapy treatment is on schedule and appears headed for commercial use in the near future. The company announced two developments that suggest this… Read More
I am recommending the purchase of a Molina Healthcare June 17 55 Straddle.Buy to Open Molina Healthcare June 16 55 Call Option (MOH_170616C0005500) up to $8.Buy to Open Molina Healthcare June 16 55 Put Option (MOH_170616P0005500) up to $8Rational for the trade: Molina is a leading provider of Medicaid HMO insurance… Read More
With two of our portfolio holdings staring down growing competition, I’m selling them both for gains:Arista Networks (NSDQ: ANET): Up 53% since it was recommended in March.Xilinx (NSDQ: XLNX): Up 17% since recommended in June.For more details on these stocks and the rationale behind the sales, see the full… Read More
Sell shares of Diebold Nixdorf (NYSE: DBD) and Ambarella (NSDQ: AMBA). Keep Diebold February Options Straddle open.I am recommending the sale of Diebold Nixdorf (NYSE: DBD) shares ahead of Italy’s referendum due to the increased potential risk to companies doing business in the Eurozone if the “No” vote prevails. Read More
Four stocks have been sold out of the Special Situations portfolio and one buy limit was adjusted in the Breakthrough Tech portfolio.Click on the company name for a link to the original article.Special Situations Sells:Bel Fuse (NSDQ: BELFB)NXP Semiconductors (NSDQ: NXPI)NICE Systems (NSDQ: NICE)Juno Therapeutics (NSDQ: JUNO)Breakthrough… Read More
It’s time to give thanks and take profits on the Texas Instruments January 70 call option. I recommended the the option along with the stock in the September issue of Breakthrough Tech Profits. And while the stock has done well- up nearly 11% as of the close on 11/22/16 –… Read More
It’s time to sell this straddle. I recommended the trade as a hedge against the election which Wall Street has surprisingly handled fairly well. Because of the relatively low volatility in the market after the election and the slow and steady move to the upside, the large move required to… Read More